Zheng Qizhi, Peskoe Sarah B, Ribas Judit, Rafiqi Fatema, Kudrolli Tarana, Meeker Alan K, De Marzo Angelo M, Platz Elizabeth A, Lupold Shawn E
Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Prostate. 2014 Dec;74(16):1655-62. doi: 10.1002/pros.22883. Epub 2014 Sep 22.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate a broad array of cellular and disease processes. Several miRNAs are differentially expressed in cancer and many are being considered as biomarkers for predicting clinical outcomes. Here we quantified the expression of three miRNAs, miR-21, miR-141, and miR-221, from prostate cancer surgical specimens and evaluated their association with disease recurrence after primary therapy.
A pilot nested case-control study was designed from a large cohort of men who underwent radical prostatectomy between 1993 and 2001. Total RNA was extracted from malignant prostate tissue of 59 cases (recurrence) and 59 controls. Cases and controls were matched on age, race, pathologic stage, and grade. The relative expression of each miRNA was then determined for each sample by quantitative real-time RT-PCR. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of recurrence for tertiles of miRNA expression. We noted block storage time effects and thus, used separate tertile cutpoints based on the controls by calendar year of prostatectomy.
Lower miR-221 expression was associated with a higher risk of recurrence; the ORs were 3.21 for the lowest tertile and 2.63 for the middle tertile compared with the highest tertile of expression (P-trend = 0.02). This pattern was unchanged after multivariable adjustment (P-trend = 0.05). No statistically significant trends were observed for miR-21 or miR-141 after multivariable adjustment.
Based on this small pilot study, men with localized prostate cancers with lower miR-221 expression may have a greater risk for recurrence after surgery.
微小RNA(miRNA)是一类小的非编码RNA,可调节广泛的细胞和疾病过程。几种miRNA在癌症中差异表达,许多miRNA被视为预测临床结果的生物标志物。在此,我们对前列腺癌手术标本中三种miRNA(miR-21、miR-141和miR-221)的表达进行了定量,并评估了它们与初始治疗后疾病复发的相关性。
从1993年至2001年间接受根治性前列腺切除术的大量男性队列中设计了一项先导性巢式病例对照研究。从59例(复发)和59例对照的恶性前列腺组织中提取总RNA。病例和对照在年龄、种族、病理分期和分级方面进行匹配。然后通过定量实时RT-PCR确定每个样本中每种miRNA的相对表达。使用条件逻辑回归来估计miRNA表达三分位数的复发比值比(OR)和95%置信区间(CI)。我们注意到了样本存储时间的影响,因此,根据前列腺切除术的历年对照情况使用了单独的三分位数切点。
较低的miR-221表达与较高的复发风险相关;与最高表达三分位数相比,最低三分位数的OR为3.21,中间三分位数的OR为2.63(P趋势=0.02)。多变量调整后这种模式未改变(P趋势=0.05)。多变量调整后,miR-21或miR-141未观察到统计学上的显著趋势。
基于这项小型先导性研究,miR-221表达较低的局限性前列腺癌男性术后复发风险可能更高。